Gelesis Holdings, Inc. Stock price Nyse

Equities

CPSR

US36850R2040

Pharmaceuticals

Delayed Nyse 10:04:16 2024-03-20 am EDT 5-day change 1st Jan Change
0.0198 USD +1,979,900.00% Intraday chart for Gelesis Holdings, Inc. +1,299,900.00% -99.61%
Sales 2021 11.18 Sales 2022 25.77 Capitalization 21.21M
Net income 2021 -93M Net income 2022 -55M EV / Sales 2021 34,107,465 x
Net Debt 2021 37.87M Net Debt 2022 54.85M EV / Sales 2022 2,951,835 x
P/E ratio 2021
-0.12 x
P/E ratio 2022
-0.21 x
Employees 93
Yield 2021 *
-
Yield 2022
-
Free-Float 47.3%
More Fundamentals * Assessed data
Dynamic Chart
Motion for Joint Administration Approved for Gelesis Holdings, Inc. CI
Motion for Joint Administration Filed by Gelesis Holdings, Inc. CI
Gelesis Holdings Provides Information to Shareholders CI
Gelesis Holdings, Inc. Filed for Bankruptcy CI
PureTech Health plc cancelled the acquisition of the remaining 76.7% stake in Gelesis Holdings, Inc. from Pacific Investment Management Company LLC, Hpso Spv Limited, SSD2 LLC, Cms Medical Venture Investment (HK) Limited and others. CI
Gelesis Holdings, Inc. Appoints Mr. Yishai Zohar as Interim Principal Financial Officer CI
Gelesis Holdings, Inc. Appoints Mr. Yishai Zohar as Chief Compliance Officer, Corporate Secretary, Treasurer, Principal Accounting Officer CI
Gelesis Holdings, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023 CI
Orgenesis Names Elliot Maltz Chief Financial Officer MT
Elliot Maltz, the Chief Financial Officer of Gelesis Holdings, Inc. Resigns, Effective August 15, 2023 CI
Elliot Maltz, Treasurer, Chief Compliance Officer and Corporate Secretary (And Principal Financial and Accounting Officer) of Gelesis Holdings, Inc. Resigns from All Positions, Effective August 15, 2023 CI
Gelesis Holdings, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023 CI
Gelesis Holdings, Inc. announced that it has received $2 million in funding from PureTech Health LLC CI
Gelesis Holdings, Inc. Announces Board Changes CI
Gelesis Holdings, Inc. Announces Resignation of Dominic Perks as Class I Director CI
More news
1 day+1,979,900.00%
Current month-99.61%
Current year-99.61%
More quotes
3 years
0.01
Extreme 0.013
12.23
5 years
0.01
Extreme 0.013
12.23
10 years
0.01
Extreme 0.013
12.23
More quotes
Date Price Change Volume

Delayed Quote Nyse, March 20, 2024 at 10:04 am EDT

More quotes
Gelesis Holdings, Inc. is a commercial stage biotherapeutics company built for consumer engagement. The Company focuses on advancing superabsorbent hydrogel therapeutics for chronic gastrointestinal (GI) diseases including excess weight, type two diabetes, Nonalcoholic Fatty Liver Disease (NAFLD)/ Nonalcoholic Steatohepatitis (NASH), functional constipation (FC), and inflammatory bowel disease. Its product, Plenity, is an orally administered capsule. Plenity is available by prescription via a telehealth consultation with a physician trained in weight management support, with free, unlimited follow-up visits as needed. Consumers can visit myplenity.com for online consultations. Its other pipeline candidate includes GS200 for weight loss in prediabetes and type two diabetes. It is also developing GS300 for the treatment of NAFLD and NASH, and GS500 for the treatment of Functional Constipation (FC).
More about the company

Annual profits - Rate of surprise

  1. Stock
  2. Equities
  3. Stock Gelesis Holdings, Inc.
  4. Stock Gelesis Holdings, Inc. - Nyse